Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners

发展 SENISCA 的全球网络以满足未来需求：拨款申请、寡核苷酸合成和制药合作伙伴

• 批准号: 10018782
• 金额: $ 2.53万
• 依托单位: SENISCA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10018782
• 关键词: Developing; SENISCA; global; network; meet

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cell aging. This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate aged cells.At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.Because oligonucleotide therapeutics is one of the fastest-growing therapeutic sectors globally, cutting edge cell delivery technologies are in constant and fast-moving development. To stay abreast of these developments, SENISCA needs to dedicate a strong internal team to the task of securing world leading partnerships for oligonucleotide synthesis and cell delivery in-licensing. This will be a key success factor in our ability to reach Phase 1 to Phase 3 clinical-testing stage for our drug pipeline, and ensure that SENISCA becomes a leading Oligonucleotide therapeutics company globally. The success of these partnerships will also provide a solid foundation to bid for collaborative EU-based grant opportunities and open the door to future co-development pharmaceutical partnerships.We will be assigning research tasks to members of the SENISCA team, sub-contracting research to a drug development market specialist, and sourcing a pharmaceutical partnering agency to assist us with our partner search. We also aim to attend at least one networking event/conference in early 2022 (either online or in person) to increase our international network and visibility.This project will lead to innovation within the senescence field. SENISCA is proposing effective treatments (and potentially cures) for age-related diseases such as Idiopathic Pulmonary Fibrosis (IPF), Osteoarthritis (OA) and Age-related Macular Degeneration (AMD). These diseases currently have limited treatment and no cure. By starting the search for global partners, we will allow for the exchange of scientific knowledge and expertise, and we will accelerate SENISCA's R&D and route towards commercialisation.

SENISCA是一家来自埃克塞特大学的生物技术衍生公司，成立于2020年，致力于开发逆转细胞衰老的新方法（senotherapeutics）。我们的创始人是分子和细胞生物学领域的世界领导者，并为逆转细胞衰老的创新提供专利保护。这项创新通过恢复细胞的能力来“微调”其基因的表达，以恢复衰老细胞的活力。在SENISCA，我们正在利用这一知识，关于细胞如何以及为什么衰老，开发新一代的基于阿糖胞苷的干预措施，逆转衰老细胞中的衰老时钟，并针对衰老的疾病和美学迹象。因为寡核苷酸疗法是最快的-随着全球治疗领域的不断发展，尖端的细胞递送技术正在不断快速发展。为了跟上这些发展的步伐，SENISCA需要投入一个强大的内部团队，以确保寡核苷酸合成和细胞交付许可方面的世界领先合作伙伴关系。这将是我们能够使我们的药物管道达到1期至3期临床试验阶段的关键成功因素，并确保SENISCA成为全球领先的寡核苷酸治疗公司。这些合作伙伴关系的成功也将为竞标欧盟合作赠款机会提供坚实的基础，并为未来的共同开发制药合作伙伴关系打开大门。我们将向SENISCA团队成员分配研究任务，将研究分包给药物开发市场专家，并聘请制药合作机构协助我们寻找合作伙伴。我们还计划在2022年初参加至少一次网络活动/会议（在线或亲自），以增加我们的国际网络和知名度。该项目将导致衰老领域的创新。SENISCA提出了有效的治疗（和潜在的治愈）与年龄有关的疾病，如特发性肺纤维化（IPF），骨关节炎（OA）和视网膜相关的黄斑变性（AMD）。这些疾病目前治疗有限，无法治愈。通过开始寻找全球合作伙伴，我们将允许科学知识和专业知识的交流，我们将加快SENISCA的研发和商业化路线。